


Summary

In one aspect, there is provided a compound of formula (I), including any stereochemically isomeric form thereof, wherein




including any stereochemically isomeric form thereof, wherein


X is N or CR⁶ wherein R⁶ is hydrogen, halo or C₁₋₄alkyl;

R¹ is CH₃ or CH₂CH₃, and R^{1'} is hydrogen; or R¹ and R^{1'} are taken together with the carbon atom to which they are attached to form cyclopropyl; and R² is C₃₋₆alkyl and R³ is C₁₋₄alkyl;


or the moiety is a radical of formula :




(a-1)




(a-2)




(a-3)




(a-4)




(a-5)




(a-6)




(a-7)




(a-8)




(a-9)




(a-10)




(a-11)




(a-12)




(a-13)



(a-14)



(a-15)



wherein R^1 is CH_3 or CH_2CH_3 , and $R^{1'}$ is hydrogen; or $R^{1'}$ is absent in radical (a-6);
 or R^1 and $R^{1'}$ are taken together with the carbon atom to which they are attached to
 form cyclopropyl; and radical (a-1) to (a-30) are optionally substituted with one or two
 substituents each independently selected from C_{1-2} alkyl and halo;

R^4 is C_{1-6} alkyl; C_{3-6} alkenyl, polyhalo C_{1-4} alkyl; C_{1-4} alkyl substituted with one
 C_{3-6} cycloalkyl; aminocarbonyl, mono- or di(C_{1-4} alkyl)aminocarbonyl;
 oxetanyl optionally substituted with C_{1-4} alkyl; Heteroaryl¹; C_{3-6} cycloalkyl;
 C_{3-6} cycloalkyl substituted with one or two substituents each individually
 selected from hydroxy, halo, cyano, C_{1-4} alkyl, C_{1-4} alkyloxy, polyhalo C_{1-4} alkyl,
 and polyhalo C_{1-4} alkyloxy; or

NR^7R^8 wherein R^7 is selected from hydrogen and C_{1-4} alkyl;

R^8 is C_{1-4} alkyl or C_{3-6} cycloalkyl;

or R^7 and R^8 are taken together with the nitrogen to which they are attached to
 form azetidiny, pyrrolidinyl or piperidinyl;

R^5 is C_{3-6} cycloalkyl;

Heteroaryl;

Bicycle;

naphthyl substituted with 1, 2 or 3 substituents each independently selected
from halo and hydroxycarbonyl;
phenyl substituted with 1, 2 or 3 substituents each independently selected from
hydroxy;
5 halo;
C₁₋₆alkyl;
C₁₋₆alkyl substituted with one, two or three substituents each
independently selected from halo, hydroxy,
10 hydroxycarbonyl, aminocarbonyl, Heterocycle,
C₃₋₆cycloalkyl, C₃₋₆cycloalkyl substituted with one or two
substituents each independently selected from C₁₋₄alkyl,
halo, hydroxycarbonyl, and C₁₋₄alkyl substituted with
hydroxycarbonyl;
C₃₋₆alkenyl;
15 C₃₋₆alkenyl substituted with one or two substituents selected from
C₁₋₆alkyl, hydroxy, hydroxycarbonyl and aminocarbonyl;
C₃₋₆alkynyl;
C₃₋₆alkynyl substituted with one hydroxycarbonyl;
C₃₋₆cycloalkyl;
20 C₃₋₆cycloalkyl substituted with one, two or three substituents each
independently selected from C₁₋₄alkyl, halo,
hydroxycarbonyl, and C₁₋₄alkyl substituted with
hydroxycarbonyl;
C₃₋₆cycloalkenyl;
25 C₃₋₆cycloalkenyl substituted with one hydroxycarbonyl;
C₁₋₆alkyloxy optionally substituted with hydroxycarbonyl;
polyhaloC₁₋₄alkyl;
polyhaloC₁₋₄alkyloxy;
cyano;
30 nitro;
B(OH)₂;
hydroxycarbonyl;
CO-NHOH;
CO-NR⁹R¹⁰;
CO-NH-NR⁹R¹⁰;
35 NR⁹R¹⁰;
NH-CO-R¹¹;
NH-CO-O-R¹¹;

NH-CO-NH-R¹¹;
NH-CS-NH-R¹¹;
NH-C=(N-CN)-NH-R¹¹;
aminosulfonyl; mono- or di(C₁₋₄alkyl)aminosulfonyl;
Heterocycle; and
spiro[3.3]heptanyl optionally substituted with hydroxycarbonyl;

wherein

R⁹ and R¹⁰ are each independently selected from hydrogen; C₁₋₆alkyl; SO₂-R¹²; and
C₁₋₆alkyl substituted with one or two substituents each independently selected
from hydroxy, hydroxycarbonyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkyl substituted with
hydroxycarbonyl, C₁₋₄alkylcarbonylamino, mono- or di(C₁₋₄alkyl)amino, and
Heterocycle;

R¹¹ is C₁₋₆alkyl; C₃₋₆alkenyl; C₃₋₆cycloalkyl; Aryl; Heterocycle; or C₁₋₆alkyl
substituted with one substituent selected from C₃₋₆cycloalkyl, C₁₋₄alkyloxy,
hydroxy, cyano, hydroxycarbonyl, aminocarbonyl, mono- or
di(C₁₋₄alkyl)aminocarbonyl, C₁₋₄alkylcarbonylamino, and Heterocycle;

R¹² is C₁₋₄alkyl, C₃₋₆cycloalkyl, or C₁₋₄alkyl substituted with one C₃₋₆cycloalkyl,
Heteroaryl is thienyl, imidazolyl, pyrazolyl, thiazolyl, pyridinyl, 1-benzopyrazolyl,
2,3-dihydro-1H-indolyl, 2-oxo-2,3-dihydro-1H-indolyl, quinolinyl, 2-oxo-
quinolinyl, benzimidazolyl, cinnolinyl, or 2H-chromenyl, wherein each
Heteroaryl is optionally substituted with one or two substituents each
independently selected from C₁₋₄alkyl, halo, amino, aminocarbonyl, and
NH-CO-C₃₋₆cycloalkyl;

Heteroaryl¹ is imidazolyl or pyrazolyl; wherein each Heteroaryl¹ is optionally
substituted with one or two substituents each independently selected
from C₁₋₄alkyl, halo and hydroxycarbonyl;

Heterocycle is azetidiny, tetrahydrofuranyl, pyrrolidinyl, furanyl, thienyl, imidazolyl,
pyrazolyl, thiazolyl, oxazolyl, isoxazolyl, 1,2,4-oxadiazolyl, 2,5-dihydro-1H-
pyrrolyl, pyridinyl, pyrimidinyl, pyrazinyl, 2-oxo-azepanyl, 2,5-dioxopyrrolidinyl,
or 3-oxo-2,3-dihydro-1,2-oxazolyl; wherein each Heterocycle is optionally
substituted with one or two substituents each independently selected from
C₁₋₄alkyl, C₃₋₆cycloalkyl, halo, hydroxyC₁₋₄alkyl, polyhaloC₁₋₄alkyl,
hydroxycarbonyl, and C₁₋₄alkyl substituted with hydroxycarbonyl;

Aryl is phenyl substituted with one or two substituents each independently selected
from hydrogen, halogen, C₁₋₄alkyl, C₁₋₄alkyloxy, and trifluoromethyl;

Bicycle is 1,2,3,4-tetrahydronaphthalenyl, chromanyl or 2,3-dihydrobenzofuranyl;
wherein each Bicycle is optionally substituted with one or two substituents
each independently selected from C₁₋₄alkyl, halo and hydroxycarbonyl;

with the proviso that [7-ethyl-2-(3-thienyl)pyrazolo[1,5-a]pyrimidin-5-yl](2-methyl-1-piperidiny)-methanone and [7-ethyl-2-(2-pyridinyl)pyrazolo[1,5-a]pyrimidin-5-yl](2-methyl-1-piperidiny)-methanone are not included;
or a pharmaceutically acceptable acid addition salt thereof.

5

In another aspect, there is provided a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically active amount of a compound as defined herein.

10 In another aspect, there is provided a process for preparing a pharmaceutical composition as defined herein wherein a therapeutically active amount of a compound as defined herein is intimately mixed with a pharmaceutically acceptable carrier.

In another aspect, there is provided a compound as defined herein for use as a medicine.

15

In another aspect, there is provided a compound as defined herein, or a pharmaceutical composition as defined herein, for use in the treatment of a respiratory syncytial virus infection.

20 In another aspect, there is provided use of a compound of formula (I) as defined herein in the manufacture of a medicament for the treatment of a respiratory syncytial virus (RSV) infection.

12. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically active amount of a compound as claimed in any of claims 1 to 11.
- 5 13. The pharmaceutical composition according to claim 12, which further comprises another antiviral agent.
14. The pharmaceutical composition according to claim 13, wherein the other antiviral agent is a RSV inhibiting compound.
- 10 15. A process for preparing a pharmaceutical composition as claimed in any one of claims 12 to 14 wherein a therapeutically active amount of a compound as claimed in any of claims 1 to 11 is intimately mixed with a pharmaceutically acceptable carrier.
- 15 16. A compound as claimed in any of claims 1 to 11 for use as a medicine.
17. A compound as claimed in any of claims 1 to 11, or a pharmaceutical composition as claimed in claim 11, for use in the treatment of a respiratory syncytial virus infection.
- 20 18. Use of a compound of formula (I) as defined in any one of claims 1 to 11 in the manufacture of a medicament for the treatment of a respiratory syncytial virus (RSV) infection.